From EGFR mutations to STAT30-driven resistance in NSCLC: Biomarkers and multi-modal treatment approach

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Non-small-cell lung cancer (NSCLC) is a leading cause of cancer mortality, often complicated by drug resistance and immune evasion.
• Activating mutations or overexpression of the Epidermal Growth Factor Receptor (EGFR) pathway are key drivers in NSCLC.
• The Signal Transducer and Activator of Transcription 3 (STAT3) pathway plays a critical role in cancer progression and immune evasion.

Purpose of the Study:

• To examine the crosstalk between EGFR and STAT3 signaling in NSCLC.
• To critically evaluate current and emerging therapeutic strategies targeting EGFR, STAT3, and immune checkpoints.
• To propose an integrated framework for combination therapies in NSCLC.

Main Methods:

• Review and analysis of preclinical studies and clinical trial data.
• Investigation of EGFR-induced STAT3 phosphorylation and its downstream transcriptional targets (Snail, Twist, ZEB1).
• Comparative analysis of monotherapy versus combination treatment regimens.

Main Results:

• EGFR activation leads to STAT3 phosphorylation, influencing transcription factors involved in epithelial-mesenchymal transition (EMT).
• Preclinical studies suggest synergistic effects of combining EGFR tyrosine kinase inhibitors (TKIs) with STAT3 inhibitors or immune checkpoint inhibitors (ICIs).
• Specific agents like Polyphyllin I and MTI31 show potential in reversing EMT and restoring sensitivity to EGFR-targeted therapy.

Conclusions:

• Significant crosstalk exists between EGFR and STAT3 signaling in NSCLC, contributing to therapeutic resistance.
• While preclinical data support combination therapies, clinical evidence is still limited.
• An integrated approach co-targeting EGFR, STAT3, and immune checkpoints may enhance treatment efficacy in NSCLC.